Brief: eFFECTOR Therapeutics Inc Reports Q3 Diluted Loss Per Share Of $0.23
Nov 7 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR THERAPEUTICS REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
* EFFECTOR THERAPEUTICS INC - QTRLY DILUTED LOSS PER SHARE
$0.23
Source text for Eikon: ID:nGNX7szRkW
Further company coverage: EFTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Effector Therapeutics
See all newsBrief: Effector Therapeutics Expects To Incur One-Time Charges And Cash Expenditures
Brief: Effector Therapeutics Announces It Will Wind Down Operations
Brief: Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
eFFECTOR Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: eFFECTOR Therapeutics Enters Into An At The Market Offering Agreement With H.C. Wainwright